Fist Assist Devices, LLC Announces Formation of a Global Medical Advisory Board

Today Fist Assist Devices announced the formation of a new global medical advisory board.

The company developed the only wearable patent-protected intermittent compression device for vein dilation for patients with end-stage renal disease (ESRD). The non-invasive device provides intermittent pressure to a specific arm vein, with the goal of helping dilate the vein after fistula placement. Providing better vein dilation for hemodialysis patients can ensure that the fistula reaches optimal size without delays or extra procedures, ultimately reducing costs for both patients and the dialysis providers.

“As Fist Assist Devices, LLC prepares for its global commercialization launch, initially commencing in India this summer, the global MAB was developed to counsel the company on maximizing opportunities to advance outcomes, lower costs and improve patients’ end-stage renal disease journey,” said Tej Singh M.D., CEO and Founder of Fist Assist Devices, LLC.

The new global MAB advisors include:

  • Dr. John Ross (Orangeburg, S.C., United States), Medical Director, Dialysis Access Institute, Regional Medical Center
  • Dr. Alexandros Mallios (Paris, France), Vascular Surgery Faculty, Institut Mutualiste Montsouris
  • Dr. Sanjay Desai (Bangalore, India), Chief, Vascular Surgery, MS Ramaiah Memorial Hospital
  • Dr. Jaime Velez (Cali, Colombia), Chief, Vascular Surgery, Clinica Farallones
  • Dr. Jackie Ho Pei (Singapore), Director, Endovascular Therapy, Vascular Surgery Division, National University Heart Centre

“I am thrilled to be associated with Fist Assist Devices, LLC and its revolutionary device to assist in vein dilation. The device will be critical for patients with stage 4 or 5 kidney failure as they manage through end-stage renal disease,” said Dr. John Ross, a globally renowned vascular access thought leader and chair of the newly formed MAB. “Fist Assist is the missing link to managing ESRD patients because the device has the potential to significantly lower costs for patients and the healthcare system, from fistula placement to maturation.”